🇺🇸 FDA

Company profile · Sponsor

Elan

Elan Pharma International

EC35AB7 · EMA pharma EU
Pipeline
14
Drugs
0
Patents
0

Quick answer

Elan (EC35AB7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EC35AB7
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (14)

Search pipeline →

  1. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan

    Myopia

    phase 3 small molecule active

    1 trial

  2. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  3. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  4. INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0

    Elan

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  5. INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80

    Elan

    Immunoglobulin G4-related disease (IgG4-RD)

    phase 3 small molecule active

    1 trial

  6. Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant

    Elan

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  7. Fipaxalparant

    Elan

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  8. Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc

    Elan

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  9. HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116

    Elan

    Sjögren’s Syndrome

    phase 2 small molecule active

    1 trial

  10. INEBILIZUMAB

    Elan

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  11. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  12. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  13. WVE-006

    Elan

    Alpha-1 antitrypsin deficiency (AATD)

    phase 2 small molecule active

    1 trial

  14. A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

    Elan

    Adults Living with Overweight and Obesity

    phase 1 other active

    1 trial

Frequently asked questions

What is Elan?

Elan (EC35AB7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Elan sponsor?

We track 14 ClinicalTrials.gov-linked programs for Elan, including Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance. and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Elan company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.